ImmuPharma (IMM) Competitors GBX 1.56 -0.01 (-0.63%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines IMM vs. OKYO, OBI, HEMO, AOR, RLM, NSCI, OPTI, ONC, SNG, and BVXShould you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include OKYO Pharma (OKYO), Ondine Biomedical (OBI), Hemogenyx Pharmaceuticals (HEMO), AorTech International (AOR), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), Oncimmune (ONC), Synairgen (SNG), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry. ImmuPharma vs. OKYO Pharma Ondine Biomedical Hemogenyx Pharmaceuticals AorTech International Realm Therapeutics NetScientific OptiBiotix Health Oncimmune Synairgen BiVictriX Therapeutics ImmuPharma (LON:IMM) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Is IMM or OKYO more profitable? ImmuPharma's return on equity of -111.20% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ImmuPharmaN/A -111.20% -43.00% OKYO Pharma N/A -397.13%-154.72% Does the MarketBeat Community favor IMM or OKYO? ImmuPharma received 259 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote. CompanyUnderperformOutperformImmuPharmaOutperform Votes26676.44% Underperform Votes8223.56% OKYO PharmaOutperform Votes763.64% Underperform Votes436.36% Which has more risk & volatility, IMM or OKYO? ImmuPharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Which has better valuation & earnings, IMM or OKYO? ImmuPharma has higher revenue and earnings than OKYO Pharma. ImmuPharma is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuPharma£94.82K68.73-£2.46M-£0.01-156.50OKYO PharmaN/AN/A-£6.70M-£0.01N/A Does the media refer more to IMM or OKYO? In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Overall Sentiment ImmuPharma Neutral OKYO Pharma Neutral Do institutionals & insiders hold more shares of IMM or OKYO? 17.4% of ImmuPharma shares are held by institutional investors. 48.3% of ImmuPharma shares are held by insiders. Comparatively, 31.9% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryImmuPharma beats OKYO Pharma on 9 of the 10 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMM vs. The Competition Export to ExcelMetricImmuPharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.52M£151.56M£5.21B£1.71BDividend Yield0.77%3.64%5.53%7.32%P/E Ratio-156.50182.3084.151,718.32Price / Sales68.7317,316.051,248.61267,691.18Price / Cash20.5012.1540.9726.05Price / Book1.577.557.202.96Net Income-£2.46M-£19.43M£119.63M£178.62M7 Day Performance-6.98%0.48%2.12%-0.01%1 Month Performance-12.72%7.50%-2.43%-0.43%1 Year Performance-8.61%29.77%34.55%26.78% ImmuPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMImmuPharmaN/AGBX 1.57-0.6%N/A-8.6%£6.52M£94,819.00-156.5013OKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap DownOBIOndine BiomedicalN/AGBX 8.13flatN/A-2.9%£22.53M£1.63M-270.83N/ANews CoverageHEMOHemogenyx PharmaceuticalsN/AGBX 1.53+6.3%N/A-52.5%£20.44MN/A-152.5014News CoverageGap UpAORAorTech InternationalN/AGBX 123.50-2.4%N/AN/A£19.99M£539,000.00-33.383RLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/A-18.9%£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 12.25-5.8%N/A-53.3%£12.00M£1.26M-408.331Gap DownONCOncimmuneN/AGBX 15.15+0.3%N/A-27.6%£11.23M£1.21M-504.6752Positive NewsSNGSynairgenN/AGBX 4.63+0.9%N/A-31.1%£9.32M£79,000.00-146.6034Gap UpBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/A-9.1%£8.25MN/A-250.0017Gap UpHigh Trading Volume Related Companies and Tools Related Companies OKYO Alternatives OBI Alternatives HEMO Alternatives AOR Alternatives RLM Alternatives NSCI Alternatives OPTI Alternatives ONC Alternatives SNG Alternatives BVX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:IMM) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
